This content is only available within our institutional offering.
02 Mar 2018
The Monthly
1pm, 49.0 | Abzena, 19.0 | Advanced Oncotherapy, 44.5 | Allergy Therapeutics, 25.5 | Alliance Pharma, 78.2 | Arbuthnot Banking Group, 1,480 | Avacta Group, 31.0 | Bionomics, 0 | Burford Capital, 1,492 | Chamberlin, 90.0 | City Of London Investment Group, 440 | Collagen Solutions, 3.8 | Diurnal Group, 195 | Evgen Pharma, 13.0 | Gateley, 158 | Genedrive, 38.5 | Inland Homes, 63.9 | Morses Club, 138 | Murgitroyd Group, 580 | Non-Standard Finance, 66.0 | Obtala, 9.2 | Oxford Biomedica, 12.0 | PPHE Hotel Group, 1,150 | Premaitha Health, 4.5 | Primary Health Properties, 111 | R.E.A, 293 | Redx Pharma, 9.8 | Scancell, 12.1 | Surface Transforms, 14.0 | 600 Group, 16.2 | Tissue Regenix Group, 11.5 | Titon, 177 | ValiRx, 3.1
-
-
-
Mark Thomas
-
48 pages
-
